All News

Get a first look at can’t-miss sessions from day 2 of FMX 2025—from vaccines and metabolic health to dementia, women’s care, and AI in family medicine.

Semaglutide and tirzepatide "should be first-line treatment" for people with obesity and its myriad of complications, says EU obesity professional association.

From vaccines to reproductive health to AI, here are 16 sessions you won't want to miss at FMX 2025.

The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.

FDA did not announce the September 30 approval, which took place despite strong partisan opposition and during an uncompleted review of the drug's safety.

Moore describes the ACIP's shared decision making approach to COVID-19 vaccination as a "passive recommendation" that will surely exclude at-risk US populations.

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

The premonitory constellation of neurologic, autonomic, and behavioral symptoms is increasingly understood as the earliest manifestation of migraine pathophysiology.

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.